Lenvatinib acts on platelet‑derived growth factor receptor β to suppress the malignant behaviors of gastric cancer cells

• Published in: Oncology letters Vol. 28; no. 4; p. 483
• Main Authors: Tong, Xiaoyi, Du, Jun, Jiang, Qiaoling, Wu, Qiaoli, Zhao, Shuxia, Chen, Shuhang
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications UK Ltd 01.10.2024; D.A. Spandidos
• Subjects: Apoptosis; Bioinformatics; Biotechnology; Cancer therapies; Gastric cancer; Genomes; Growth factors; Kinases; Ligands; Medical prognosis; Mortality; Proteins; Reagents; platelet-derived growth factor receptor; tyrosine kinase inhibitor; gastric cancer; lenvatinib
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2024.14616

Given the limited treatment options and high mortality rates associated with gastric cancer, there is a need to explore novel therapeutic options. The present study aimed to investigate the efficacy of lenvatinib, a multi-target tyrosine kinase inhibitor, in mitigating the progress of gastric cancer . Comprehensive analyses were conducted to assess the impact of lenvatinib on gastric cancer cells, focusing on the inhibition of viability, suppression of proliferation, induction of apoptosis and reduction of metastatic potential. The effects of lenvatinib on these activities were determined using 5-ethynyl-2'-deoxyuridine staining, colony formation assay, flow cytometry, western blotting, scratch assay and Transwell assay. In addition, bioinformatics analyses were employed to identify key regulatory targets of lenvatinib, with particular attention given to platelet-derived growth factor receptor β (PDGFRB). In addition, the effects of PDGFRB overexpression on the regulation of lenvatinib were explored. Lenvatinib demonstrated significant inhibitory effects on the viability, proliferation and metastatic capabilities of MKN45 and HGC27 gastric cancer cell lines. Bioinformatics analyses identified PDGFRB as a crucial target of lenvatinib, with its downregulation showing promise in enhancing overall survival rates of patients with gastric cancer. By contrast, PDGFRB overexpression reversed the effects of lenvatinib on cells. The present findings underscore the potential of lenvatinib as a promising therapeutic option in the treatment of gastric cancer. By elucidating its mechanism of action and identifying PDGFRB as a primary target, the present study may aid further clinical advancements.